

Application for guidance by the Ethics Commission on carrying out a medical-scientific project which does not include the clinical trial of a drug

1. Title of the study	European registry for ICD and CRT devices in paediatric and adult patients with congenital heart disease (Euripides Registry). A joint project of the AEPC Arrhythmia Working Group and the ESC Working Group 22 (Grown-up Congenital Heart Disease), in the context of the National Register for Congenital Heart Disease (registered association).
2. Ethics Commission Application Number	<i>(to be allocated by the EC)</i>
3. Decisions of other Ethics Commissions on the same matter	A separate ethics vote by the appropriate authority must be obtained for each country that elects to participate.
4. Subject and objectives of the study (hypotheses, divided into primary and secondary hypotheses)	Paediatric and adult patients in Europe with congenital heart disease who are being treated with an implantable cardioverter defibrillator (ICD) or with cardiac resynchronization therapy (CRT) will be recorded in this registry. The objective is to be able, for the first time, to evaluate the progress of the disease over a long period by recording data on implantations and annual follow-ups on a wide-scale and long-term basis. This should help to clarify any outstanding research questions about ICD/CRT therapy.
5. Explanation of the significance of the study	Until now, there has been a lack of experience in using ICD and CRT in patients with congenital heart defects. The wide-scale recording of data on ICD/CRT devices makes it possible to review the long-term successes or complications of the therapy employed, and will help to make up for the previous lack of knowledge in this area, so that the respective treatment can be optimised. Thanks to the co-operation of both sponsors, the Association for European Paediatric Cardiology (AEPC) and the European Society of Cardiology (ESC), paediatric and adult patients will only have to be registered once, without the data having to be re-entered when the child becomes an adult.
6. Which of the following provisions apply a) German Medical Devices Law (Medizinproduktegesetz) -pursuant to § 20 MPG (Appliance does not possess a declaration of conformity, or such declaration does exist but a different indication is being examined, or additional invasive or other burdensome tests are being carried out) or -pursuant to § 23 MPG? b) Radiation Protection Ordinance § 23 c) X-Ray Ordinance § 28 a d) Gene Technology Law e) Data protection laws	e) Data protection laws

7. If applicable: Description and definition of the test products (e.g. devices in the MPG studies; please attach enclosures)	Not applicable.
8. Significant results of pre-clinical trials or reasons for not carrying out such trials	Not applicable.
9. Significant contents and results of previous studies/applications of the products to be tested in the study	Not applicable.
10. Description of the measures/test methods envisaged and any deviations from the measures/examinations that are common medical practice (what is "routine", what is done differently in the study?)	<p>Patient recruitment and data registration: Data will be registered in collaboration with the cardiologists/paediatric cardiologists treating the patients at the centres/establishments participating in the project. The patients selected on the basis of inclusion criteria will be told about the study by the doctor treating them and asked to take part. When the patients have given their written informed consent, the treating doctor/participating centre will enter the web-based data into the central database. An ID will be allocated to every patient entered, which makes it possible for other establishments/doctors to enter further follow-up data annually. The Competence Network for Congenital Heart Defects/National Registry for Congenital Heart Defects (registered association) is responsible for the punctual and correct entry of data.</p> <p>Data evaluation It is envisaged that data will be evaluated annually by the Committee of the AEPC/ESC and the Competence Network for Congenital Heart Defects/National Registry for Congenital Heart Defects (registered association).</p>
11. Evaluation and assessment of the foreseeable risks and disadvantages of taking part in the study versus the expected benefits for participants in the study and people who may suffer from the disease in the future (risk-benefit assessment)	Participation in the study does not involve any risks for patients. All decisions regarding the selected therapy strategy will be made independently of the study. Data will only be registered descriptively in the Euripides Registry.
a. Foreseeable therapeutic benefits for study participants (individual benefits for the individual patient)	No direct therapeutic benefit for participants is expected in the short term.
b. Foreseeable medical benefits for people suffering from the disease in the future (Group benefits)	Evaluating the use of ICD and CRT for congenital heart disease makes it possible to gain precise knowledge about the practical indications, techniques, successful treatments and risks and can contribute to optimising these therapies in patient groups with congenital heart disease
c. Risks and burdens for study participants (list all individually)	The study does not involve any additional risks or burdens for participants.

12. Risk control measures	Not applicable.
13. Criteria for termination	Withdrawal of consent to take part in the study.
14. Number, age and gender of the persons involved	There are no restrictions on the number, age or gender of the patients to be recorded.
15. Statistical planning, information and biometric reasons for the number of cases and <u>signature</u> of the statistician.	Not applicable.
16. a. Presentation and, if applicable, clarification of the inclusion and exclusion criteria .	Inclusion criteria: Patients with congenital heart disease from all over Europe who are being treated with ICD and/or CRT devices.
b. Participant information (who gives this verbally and details about how much time there is between notification and consent, otherwise its contents can be referred to in an enclosure)	See enclosure.
c. Declaration of consent (its contents can be referred to in an enclosure)	See enclosure.
d. If applicable, information and consent of the legal representative (if applicable, also description of the procedure for setting up legal support)	See enclosure.
17. Measures for finding study participants (Poster?, Newspaper advertisements? Etc.)	Information and materials for doctors and patients will be made available as printed information brochures, and on the website of the Competence Network for Congenital Heart Defects/National Registry for Congenital Heart Defects (registered association). Extensive information will also be given to German and international parent associations and self-help groups such as, for example, the Bundesverband Herzkranker Kinder e. V. (BVHK). Patients for participation in the study will also be sought through publications and networks of the AEPC and ESC working groups.
18. If necessary: Reason for inclusion, and statement about the therapeutic benefit for persons who are under-age and/or not capable of consent.	The use of ICD or CRT in children with congenital heart disease has not been sufficiently researched so far. Relevant data must be acquired and evaluated so that this patient group can be offered appropriate treatment in the future.
19. Relationship between study participants and the doctor (Is the study doctor also the doctor treating the patient?)	Doctor-patient relationship

20. If necessary, declaration for possible inclusion of a sponsor or of persons dependent on study doctor.	Not applicable.
21. Measures for establishing whether a study participant is taking part in several studies at the same time or in a previous study the deadline of which has not yet expired.	Not applicable.
22. If applicable: payment of fees or reimbursement of costs to study participants (amount, what needs to be paid for?)	Not applicable.
23. If applicable: Plan for the further treatment and medical care of the persons involved after the study has finished.	Patients will continue to receive medical care from their respective doctors independently of the study.
24. If applicable: Insurance of the study participants (Confirmation of insurance and insurance conditions, insurer, scope of insurance, term of insurance)	Not applicable.
25. If applicable: documentation procedure (link to CRF sheets possible)	The data recorded annually (see forms in the enclosure) will be registered and processed in a separate database under the umbrella of the National Registry for Congenital Heart Defects (registered association).
26. If applicable: description of how the state of health of healthy persons involved should be documented.	Not applicable.
27. If applicable: methods of identifying, documenting and reporting adverse events (when, by whom and how??)	Not applicable.
28. Procedure for protecting the secrecy of the saved data, documents, and, if applicable, experiments, explanation of the coding of the data of study participants (<i>please do not use initials and date of birth as coding patterns!</i>)	Each patient is allocated a patient ID on initial registration. This number is used to save the data under a pseudonym. The registered data will be saved separately from the personal identification data, making it impossible to identify the person. Follow-up data will be entered annually using the ID generated on first registration. All statistical analyses are carried out anonymously and not linked with specific persons. The publication of the data and results also preserves anonymity.
29. Declaration of compliance with data protection laws	Data are saved in the context of the Data Protection Plan of the National Registry for Congenital Heart Defects (registered association), which is registered with the Berlin Commissioner for Data Protection and Freedom of Information ("Data security and data protection in the National Registry and Competence Network for Congenital Heart Defects", version 1.24 of 06.03.2006, Reg.-Nr. 531.390). Only persons working on the study have access to the data. The data will not be passed on to third parties without the consent of those concerned.

30. Names and addresses of the establishments incorporated in the study as study centres or study laboratories, and those of the study leaders and study doctors.	Euripides is a web-based joint register of the AEPC working group “Cardiac Dysrhythmias and Electrophysiology” and of the ESC working group “Adult Congenital Heart Disease” (WG 22), which is to cover patients throughout Europe. Coordinator/Contact partner: Dr. Ulrike Bauer, M.D., Managing Director Competence Network for Congenital Heart Defects/National Registry for Congenital Heart Defects (registered association) Augustenburger Platz 1 13353 Berlin E-mail: euripides@kompetenznetz-ahf.de
31. Details on the suitability of the test centre, particularly concerning the appropriateness of its resources and facilities, and of the staff available for carrying out clinical trials and their experience in carrying out similar studies.	The Competence Network for Congenital Heart Defects already has an established and functioning register for the uncomplicated, quality-assured and extensive registration and storage of patient data. This is the National Registry for Congenital Heart Defects (registered association), which has existed since 2000 and fulfils the requirements in terms of both technology and data protection. The people who work there are familiar with the material and have many years of expertise. It is planned to set up the Euripides Registry as a sub-register within the National Registry for Congenital Heart Disease, and thus to make use of existing structures and expertise.
32. Agreement about access to data by the examiner/main examiner/director of the clinical study, and guidelines regarding publication.	Only persons working on the study have access to the data, and participants can only access the data they have entered themselves. The scientific committee, which is made up of representatives from the specialist associations named, decides on the evaluation and use of the data. On principle, data may only be published anonymously.
33. Information about financing of the study (please refer to § 263 StGB - German Tax Law)	The resources of the existing National Registry for Congenital Heart Defects, sponsored by the German Federal Ministry for Education and Research (Bundesministerium für Bildung und Forschung – BMBF) will be used. It is also planned to finance the project with donations from industry.
a. Financing source (name and registered office)	National Registry for Congenital Heart Defects (registered association) Augustenburger Platz 1 13353 Berlin
b. Amount of calculated costs per participant and in total	See enclosure
c. Amount of cost reimbursement per participant and in total	See enclosure.

Name and signature of applicant/s:

I hereby affirm that the information given in this application is correct. It is my opinion that it is possible to carry out the above-named study in conformity with the protocol and the national statutory provisions.

I am aware that, pursuant to Section 19 Berlin Data Protection Law (BlnDSG), I am obliged to compile a description of files and procedures for the automated processing of personal data and of data which may be linked with specific persons, and that I must make this description available to the official data protection commissioner of the Charité hospital pursuant to Section 19a. I have been informed that if such procedure involves the processing of data which are subject to professional secrecy (e.g. patient/physician confidentiality), I must arrange for a prior investigation by the official data protection commissioner of Charité before the start of the procedure, in accordance with Section 5 BlnDSG, and that I may only apply the procedure when the test result is positive.

Name: Bauer

First name: Ulrike

Address: Competence Network for Congenital Heart Defects/
National Registry for Congenital Heart Defects (Reg. Ass).
Augustenburger Platz 1
13353 Berlin

Position: Managing Director

Date:

Signature:



Enclosures to be attached:

- Participant information on department letterhead
- Participant (informed) consent with data protection declaration (highlighted) on department letterhead
- Consent of department manager/institute director/clinic director
- Significant publications on the issue, if available (not more than 3)

Where appropriate:

- Separate test plan
- Examiner information about the test product
- CE certificate (Declaration of conformity) for studies in accordance with §23 MPG (Medical Devices Law)
- Certificate on the technical inspection of the medical device for studies in accordance with §20 MPG
- Certificate and conditions of insurance
- Case report forms (CRF)
- Questionnaires
- Votes by other Ethics Commissions on the same matter
- Notices/Newspaper adverts for recruitment of study participants

Important instructions:

The application must be submitted in the German language, together with the above-listed enclosures and a covering letter, **in a single written copy and also in electronic version (on a CD-ROM)**, to the office.

In addition, the following documents, **copied 12 times and stapled**, must be submitted to the office:

- Application text
- Brief summary if applicable
- Participant information (information on patient and/or test person)
- Declaration of consent
- Certificate of insurance if applicable